Gliomas are characterized by a malignant phenotype with proliferation, cell cycle arrest and invasion. To explore the biological consequences of epigenetically regulated miRNAs, we performed a microarray-based screening (whose expression was affected by 5-AZA treatment) followed by bisulfite sequencing validation. We found that miR-134 as an epigenetically regulated suppressor gene with prognostic value in gliomas. MicroRNA-134 was downregulated in high-grade gliomas, especially in GBM samples. Functional studies in vitro and in vivo in mouse models showed that overexpression of miR-134 was sufficient to reduce cell cycle arrest, cell proliferation and invasion. Target analysis and functional assays correlated the malignant phenotype with miR-134 target gene KRAS, an established upstream regulator of ERK and AKT pathways. Overall, our results highlighted a role for miR-134 in explaining the malignant phenotype of gliomas and suggested its relevance as a target to develop for early diagnostics and therapy.
Introduction
Glioblastomas is a deadly central nervous system tumor that is characterized by a complex genomic landscape and profound heterogeneity (1) . Identification of the underlying pathogenic mechanisms involved in the initiation and progression of this tumor is critical for developing more effective treatments. Cancer-specific DNA methylation changes are hallmarks of human cancers, in which global DNA hypomethylation is often seen concomitantly with hypermethylation of CpG islands (2) . Promoter CpG island hypermethylation generally results in transcriptional silencing of the associated gene.
MicroRNAs (miRNAs) are small non-coding RNAs which act as post-transcriptional regulators of gene expression. Through regulation of specific target genes, a wide variety of biologic processes including cellular differentiation, proliferation and apoptosis are regulated by miRNAs (3, 4) . Thus, deregulated expression of certain miRNAs may lead to alterations of these processes and to the development of a malignant phenotype.
Beside chromosomal loss and alterations of the miRNA processing machinery, methylation has been identified as a mechanism which may cause downregulation of miRNA gene expression in cancer cells (5, 6) . Previously, miR-34a, miR-192, miR-196b and miR-892b have been reported as examples for methylated miRNA-encoding genes (referred to as methylated miRNAs) in lung adenocarcinomas and other malignancies (7) (8) (9) . However, knowledge about methylation-mediated miRNA silencing in glioma is still very limited to date.
To gain more information about the role of methylation in miRNA silencing, we conducted a microarray-based screening for methylation regulated miRNAs. By further validation in glioma cell lines, primary tumors, normal brain tissue, in vitro and in vivo assays, we found that miR-134 was epigenetically silenced and could mitigate a malignant phenotype in gliomas.
Materials and methods

Cell culture and 5-AZA treatment
Human glioma cell lines U87, LN229, U251, SHG44, U373 and H4 were cultured in DMEM medium (Hyclone) supplemented with 10 % fetal bovine serum (Hyclone). Human astrocyte cell lines (HA) (ScienCell, Carlsbad) were cultured in AM medium (ScienCell, Carlsbad), including 500 ml of basal medium, 10 ml of fetal bovine serum and 5 ml of astrocyte growth supplement. All cells were incubated at 37°C in an atmosphere of 5% CO 2 .
To demethylate the epigenetically silenced miRNAs, these cell lines were cultured with 0.5 μM of 5-AZA (Sigma-Aldrich, St. Louis, MO) for 5 days. Fresh 5-AZA was replaced every 24 h. Cells treated with 5-AZA on days 0 and 5 were harvested for miRNA expression quantification.
MiRNA expression data from glioma tissue samples
The normalized miRNA expression data and the corresponding clinical information from the Cancer Genome Atlas (TCGA, normal brain control: N = 10; GBM samples: N = 505, http://cancergenome.nih.gov/) and Chinese Glioma Genome Atlas (CGGA, low-grade glioma (LGG): N = 63; high-grade glioma (HGG): N = 135, http://www.cgga.org.cn) were downloaded for the analysis of expression patterns of miR-134 in normal brain controls, LGG and HGG samples.
Patients and samples
Human glioma tissue samples (LGG, N = 22; HGG, N = 43) and normal brain controls (patients undergoing decompressive craniectomy for traumatic brain injury, N = 10) were obtained from Beijing Tiantan Hospital for validation of the methylation and expression status of miR-134. The tissues were collected within 30 min after resection. All tissue samples were immediately stored in liquid nitrogen after resection. This study was approved by the Ethics Committee of Beijing Tiantan Hospital, and written informed consent was obtained from all participants. All samples were histologically classified and graded according to WHO guidelines by two clinical neuropathologists.
RNA extraction and miRNA expression quantification
Total RNAs were extracted from patient tissue specimens and cell lines using TRIzol reagent (Invitrogen). Only RNA samples with RIN ≥7.0 were used for further analysis.
The miRNA expression microarray (Agilent human miRNA(8*60k) v18.0) was used for identification of epigenetically silenced miRNAs in three glioma cell lines (U251, U87, H4; before and after 5-AZA treatment).
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis was used to validate the expression pattern of miR-134 in HA, 6 glioma cell lines, 10 normal brain controls and 65 glioma tissues in the validation cohort. The experiments were performed using a standard SYBR PrimeScript miRNA RT-PCR kit (Takara, Japan) in a C1000™ Thermal Cycler and a CFX96™ Real-Time system (Bio-Rad) according to the manufacturer's protocol. The relative expression value of miRNA was calculated using comparative method after normalization against U6 rRNA (The 5ʹ-3ʹ primer of human miR-134: 5ʹ-TGTGACTGGT TGACCAGA GGG-3ʹ).
DNA extraction and bisulfite sequencing
Genomic DNA was extracted from frozen tumor tissues using the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's protocol. DNA concentration and quality were measured using the Nano-Drop ND-2000 spectrophotometer (NanoDrop Technologies, Houston, TX).
Bisulfite sequencing spanning the promoter regions of miR-134 was used for the validation of methylation status of glioma samples in the validation cohort (N = 65), Of the 14 CpG sites we tested, a sample would be considered as hypermethylated if the average methylation rate >10%, and vice versa.
MiRNA target prediction
Candidate targets of miR-134 were predicted by TargetScan v6.2 (http:// www.Targetscan.org/), PicTar (http://www.PicTar.org/) and RNA22 v2 (https://cm.jefferson.edu/rna22/). The overlapped target genes were used for further analysis.
Luciferase assay
For the luciferase reporter assay, the Luci-KRAS (containing the predicted matching regions of miR-134) and negative control (mutant region) were designed and synthesized by GenePharma Inc. (Shanghai, China). Firstly, U87 cell were transfected with an KRAS 3ʹUTR luciferase plasmid followed by transfection with miR-134 mimic or control miRNA in 12-well plates and then were collected and lysed for luciferase assay 48 h after transfection. The luciferase kit (Promega, Madison, WI) and Luciferase Reporter Assay System were used to detect the luciferase activities according to the manufacturer's protocols. The Renilla luciferase was used as normalization.
MiRNA oligo and cell transfection
Hsa-miR-134 and miR-NC (normal control) oligo were chemically synthesized by GenePharma Inc. (Shanghai, China) and transfected using the riboFECT™ CP reagent (RIBBIO, Guangzhou, China) according to the manufacturer's instructions. The further experiments would be performed within 72 h after transfection.
Lentiviruses and cell infection
Lentiviruses [miR-134 expression lentiviruses and its negative control containing the green fluorescent protein (GFP)] were packaged by GenePharma Inc. (Shanghai, China). Totally, 8 × 10 4 U87 and LN229 glioma cells were seeded in six-well plates and infected with the miR-134 and negative control lentiviruses. The expressions of the GFP were detected through the fluorescence microscopy. The further experiments would be performed when there were 80% cells expressing the GFP.
Western blotting and immunohistochemistry
Western blot and immunohistochemistry assays were performed as previously described (10) . Primary antibodies including rabbit anti-human p-ERK1/2, p-AKT, KRAS (Cell Signaling Technology), rabbit anti-human ERK, AKT (Beyotime, Jiangsu, China), mouse anti-human GAPDH (Proteintech, Chicago) and secondary antibody were HRP-conjugated anti-rabbit or antimouse IgG (ORIGENE, Beijing, China). Equal protein loading was assessed by the expression of GAPDH. The Western blots were visualized by chemiluminescence (ECL) reagents (Thermo) and Bio-Rad ChemiDoc XRS+ system (Bio-Rad). immunohistochemistry was visualized using light microscope.
Cell cycle analysis
Cells were washed with cold PBS, collected with EDTA-free trypsin and fixed with 70% ethanol in −20% overnight. DNA staining was performed by using propidium iodide (50 µg/ml) after the cells incubated with RNase A (1 mg/ml) in 37°C for 30 min. The DNA content of the cells was analyzed by an Accuri c6 flow cytometer (BD Biosciences).
Apoptosis assays
Annexin V-FITC/PI kit (BD PharMingen, San Diego, CA) was used for the detection of cell apoptosis according to the manufacturer's instructions. Briefly, U87 and LN229 cells were trypsinized and 5 × 10 5 cells were washed with PBS. Cells were then processed for labeling with Annexin V/FITC and propidium iodide (PI), and analyzed by flow cytometry. 
Colony formation assay
Colony formation assay was used to test the capacity of cell colony growth. The U87 and LN229 glioma cells were collected after transfection, and 200 cells were seeded into the six-well plates. After 2 weeks, the colonies were fixed with methanol for 10 min and stained with 1% crystal violet (Sigma) for 1 min. The number of colonies were measured.
Cell growth assays
The MTT assay was used to measure relative cell growth. U87 and LN229 cells were plated at 2 × 10 3 cells per well in 96-well plates with five replicate wells for each condition, transfected with miR-134 mimics and miR-NC mimics and measured once every 24 h from post-transfection. Twenty microliters of 5 mg/ml MTT (Sigma) was added to each well; then, the 96-well plates were incubated for 4 h. After adding 150 μl DMSO to each well, the 96-well plate was shaken on the Horizontal shaker for 15 min. The 490 nm absorbance was measured to assess the cell viability using a microplate reader.
Migration and invasion assays
Transwell chamber assay was used to evaluate the cell migration and invasion according to the manufacturer's instructions. For invasion assay, 3 × 10 4 transfected cells were seeded on the transwell insert coated (BD) with extracellular matrix, while cell migration assay did coat (Costar, NY) without extracellular matrix. After the cells were incubated at 37°C for 24 h, cells which were adherent to the upper surface of the filter were removed and stained with crystal violet (Sigma). The number of cells was counted.
Orthotopic nude mouse models and treatment
Nude mice (BALB/c-A, 4 weeks old) were purchased from the Animal Center at the Cancer Institute of the Chinese Academy of Medical Science and maintained in specific pathogen-free conditions. A nude mouse tumor xenograft model was established as previously described (11) . Twenty model mice were divided into miR-134 group and miR-NC group(n = 10/ group) To establish intracranial gliomas, after transfection with luciferase lentivirus, U87 glioblastoma cells stably expressing miR-134 or miR-NC were injected stereotactically into brain of each nude mouse (0.5 × 10 5 cells). The mice underwent bioluminescence imaging every 10 days for 40 days. Additionally, the overall survival time of the two groups was monitored. The mice bearing xenograft tumors were euthanized after 40 days. The tumor tissues were removed and fixed in formalin, and paraffin embedded sections were prepared for immunohistochemical analysis.
Statistical analysis
R (12) and GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA) were used for statistical analyses. Differences in clinical and molecular features were evaluated with the Student's t or Chi-square tests. The Student's t test was also used to differential expression analysis. The overall survival analysis was performed by Kaplan-Meier method with log-rank test. Statistical significance was defined as a two-tailed P value < 0.05.
Results
Identification of methylation regulated miRNAs in three glioma cell lines.
In order to find out the methylation silenced miRNAs that might be potential tumor suppressors in glioma pathogenesis, we treated three human glioma cell lines (U87, U251 and H4) with 5-aza-2-deoxycytidine (5-AZA). We used miRNA expression microarray to measure miRNA expression levels in each cell line. RNA was extracted on day 0 and day 5 after treatment with the DNA demethylating drug. After overlapping the differentially expressed miRNAs, only miR-134 was observed in significant commonly upregulated group ( Figure 1A ; Supplementary Figures  1-3 , Supplementary Table 1 , available at Carcinogenesis Online).
And no miRNA was in the commonly down-regulated group ( Figure 1B ; Supplementary Figures 1-3 , available at Carcinogenesis Online). We also validated miR-134 expression levels by quantitative RT-PCR (qRT-PCR) before and after treatment with 5-AZA in six glioma cell lines (U251, U373, SHG44, U87, LN229 and H4). This microRNA showed significant upregulation after 5-AZA treatment in all these cell lines ( Figure 1C ). CpG island, which is considered as key regulators in promoter methylation, is characterized by a high frequency of CG sequence in DNA. We also analyzed the DNA sequence of miR-134 promoter region (5 kb upstream), and found several CpG island regions ( Figure 1D ), which demonstrated the possibility of epigenetic regulation of miR-134 in gliomas.
MiR-134 is epigenetically downregulated in glioma tissues and correlates with improved prognosis
The expression level of miR-134 was assessed in two independent glioma datasets. The TCGA miRNA expression microarray data were derived from 10 normal brain samples and 505 GBM samples. The microarray data of CGGA contained 63 low-grade gliomas and 135 high-grade gliomas. There was a higher expression of miR-134 in GBM and high-grade glioma samples as compared to normal brain tissues and low-grade gliomas (NBT versus GBM, P = 0.0002, Figure 2A ;
LGG versus HGG, P = 0.0001, Figure 2B ). To further validate these results, the expression level of miR-134 in normal brain specimens, LGGs and high-grade gliomas were examined by using quantitative real-time PCR (qRT-PCR), and a similar expression pattern was shown (Normal versus LGG at P < 0.0001;
LGG versus HGG at P < 0.0001, Figure 2C ). The promoter methylation status of these samples was also analyzed by bisulfite sequencing. 63.64% (14/22) of LGG samples were hypomethylated while 65.12% (28/43) HGG samples were hypermethylated (P = 0.0273, Chi-square test, Figure 2D ). In the HGG samples, the miR-134 expression of 71.43% (15/21) samples in hypermethylated group were lower than median and 72.73% (16/22) samples in hypomethylated group were higher than median (P = 0.0038, Chi-square test, Figure 2E ).
In addition, we also evaluated the prognostic value of miR-134 in 198 glioma patients ( Figure 2F ) and 82 primary GBM (pGBM, Figure 2G ) patients from CGGA dataset. The results showed that patients with high expression of miR-134 had significantly longer survival (P = 0.0132 and P = 0.0307; Figure 2F and G). We then validated the prognostic value of miR-134 expression in HGG samples from validation cohort (N = 43). We observed a similar pattern.
Then, miR-134 expression and clinical characteristics, including age, gender, grade and IDH status, were tested for their relationship with overall survival using a univariate Cox proportional hazards model. The result indicated that miR-134 expression, age, grade and IDH status were associated with overall survival. After that, we performed a multivariate Cox proportional hazards analysis incorporating miR-134 expression, age, grade and IDH status. The analysis found that all features were independent (Table 1 ). Those findings indicated that miR-134 was an independent positive prognostic factor in gliomas.
KRAS is identified to be a target of miR-134
We used three publicly available databases to predict miR-134 targets: TargetScan v6.2 (http://www.Targetscan.org/), PicTar (http://www.PicTar.org/) and RNA22 v2 (https://cm.jefferson. edu/rna22/). The results indicated that eight overlapping genes (KRAS, PSD3, HIC2, PHF8, GNAO1, TCF21, STXBP1, C1orf21, Table 2 , available at Carcinogenesis Online) were potential targets of miR-134 with high possibility. Kirsten rat sarcoma viral oncogene (KRAS) which is involved in multiple oncogenic pathways has been reported in various malignancies (13) (14) (15) , including cervical cancer, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. To validate the miRNA target interaction, luciferase reporter system with a wild-type (KRAS-WT) and mutant (KRAS-MUT) sequence of KRAS 3ʹ-UTR was used ( Figure 3B ). The luciferase activity was significantly lower in miR-134 than miR-NC transfected cells in KRAS-WT group but this pattern was not encountered in cells transfected with miR-134 and miR-NC in KRAS-MUT group ( Figure 3C) . Therefore, our results showed that miR-134 directly targeted KRAS through binding its 3′-UTR region.
The downstream signaling pathways of KRAS were also examined by western blot after transfection with miR-NC or miR-134. Our experiments indicated that over-expression of miR-134 strongly decreased the phosphorylation AKT (pAKT), the phosphorylation ERK (pERK) and the expression of KRAS compared to the miR-NC group ( Figure 3D ). Then we co-transfected miR-134 with or without KRAS lentivirus. The result demonstrated that KRAS over-expression rescued the activation level of ERK and AKT ( Figure 3E) . Therefore, our experiments demonstrated that KRAS was a direct target of miR-134 and miR-134 could suppress the activation of downstream pathway of KRAS.
MicroRNA-134 could suppress the malignant phenotype of glioma cell lines
To further investigate the biological functions of miR-134 in glioma cells, U87 and LN229 glioma cells were transfected with miR-134 and miR-NC mimics. By using qRT-PCR, the miR-134 expression was significantly increased ( Figure 4A ) and the KRAS expression was significantly decreased ( Figure 4B ) in U87 and LN229 cells compared with their control groups. There was a lower proportion of cells in S/G2M phase and a higher the proportion of cells in G1/G0 phase with overexpression of miR-134 ( Figure 4C and D) . In colony formation assay, miR-134 transfection could suppress the formation of colonies while this phenomenon could be rescued by KRAS co-transfection ( Figure 4E) . In MTT assays, miR-134 overexpression significantly increased the proliferation of cells ( Figure 4F ).
To further detect the biological roles of miR-134 in gliomas, we used the transwell assay to evaluate the migratory and invasive behavior of U87 and LN229 cells. The results revealed that overexpression miR-134 triggered the suppression of the migratory and invasive ability in vitro which could be further rescued by KRAS co-transfection ( Figure 4G and H). 
MiR-134 could inhibit glioma growth in vivo
To further investigate the effect of miR-134 in vivo, we established the GBM orthotopic nude mouse model use U87 cell lines as described previously. U87 glioblastoma cells transfected and stably expressing luciferase and miR-134 or miR-NC were injected stereotactically into brains of nude mouse. 5 × 10 3 U87 cells transfected with miR-NC or miR-134 were injected, and the tumor volume was examined over time (10, 20 and 30 days) (Figure 5A ). MiR-134 group resulted in a significant reduction of the intracranial tumor volume compared with the miR-NC group.
Through the immunohistochemical analysis, miR-134 overexpression could significantly suppress the expression of KRAS and the activation of ERK and AKT pathway ( Figure 5B) . Furthermore, the overall survival time of miR-134 group was longer than miR-NC group (P = 0.0061, Figure 5C ). These results demonstrated that miR-134 could inhibit tumorigenesis and prolong the overall survival time in vivo.
Discussion
MicroRNAs play important roles by interaction with specific region of mRNA in many cellular biological functions, such as proliferation, differentiation, apoptosis and development (3, 16) .
It has been proved that miRNA may act as tumor suppressors or proto-oncogenes during tumorigenesis in many human cancers (17, 18) . Accumulated evidences indicated that miRNA might be candidates as biomarkers for diagnosis and treatment of gliomas (19, 20) . MicroRNA-134, located at 14q32 (21) was first identified as a brain-specific miRNA, localized in the synaptic-dendritic compartment of hippocampal neurons and involved in the regulation of the neuronal microstructure (22, 23) . Recent studies have demonstrated that miR-134 can inhibit proliferation, migration, invasion in lung cancer and hepatocellular carcinoma (24, 25) . Apart from these, miR-134, downregulated in glioma (26) , could discriminate oligodendrogliomas from glioblastoma (27) and inhibit glioma progression by targeting receptor tyrosine kinases (RTKs) (28), KRAS and STAT3 (29) (30) (31) (32) . Meanwhile, Semliki Forest virus (SFV) which was inserted target sequences complementary to miR-134 (SFV4miRT) may become an excellent candidate for treatment of glioma (23) . Some researches demonstrated that miR-134 boosted expression in hypoxic environment in glioma-initiating cells (33) .
However, the molecular mechanisms of miR-134 expression regulation and the downstream signaling pathways in glioma still need to be elucidated. Accumulating evidence suggests that DNA methylation could regulate miRNA expression during tumor progression (8,34,35) . In this study, by integrating high through-put data, validation data from glioma tissue samples, in vitro and in vivo assays, we proved that miR-134 could be epigenetically silenced in gliomas and could inhibit the malignant phenotypes by targeting KRAS. We verified that overexpression miR-134 could suppress cell proliferation and induce cell apoptosis due to an arrest in G0/G1 phase of the cell cycle and patients with higher miR-134 expression had significantly longer overall survival. Then we explored the role of KRAS in miR-134-mediated tumor suppression.
KRAS is one of the RAS family genes which encodes a membrane-associated 21 kDa GTP-binding protein. By switching from the GTP-bound active form to the GDP-bound inactive form, KRAS protein plays important roles in turning on or off their downstream effectors. Notably, the expression level of KRAS is positively correlated to the activity of ERK pathway and its downstream regulators [phosphorylation level of ERK (pERK), phosphorylation level of AKT (pAKT)] (36-38). Excessive activation of ERK pathway which is necessary for cell growth and AKT pathway which is essential for cell survival is significantly associated with the aggressiveness of tumors (39, 40) .
Although the mutation frequency of KRAS is relatively low [0.3% in grades II-III gliomas (41) ], it has been reported to play an active role in the progression of gliomas (42) . But the potential mechanisms are still unknown. Epigenetic or post-transcriptional regulation might be vital mechanisms. KRAS has been demonstrated as a target gene of miR-134 in other malignancies (43) (44) (45) . Our study further analyzed the relationship between miR-134 and KRAS by in vitro and in vivo assays. Our experiments indicated that the induction of miR-134 could inhibit the malignant phenotype including proliferation, cell cycle, migration and invasion by targeting KRAS.
Conclusion
In summary, our study identified miR-134 which was epigenetically silenced in gliomas and could inhibit the malignant phenotype of gliomas from three glioma cell lines. We validated that miR-134 could inhibit ERK and AKT pathway through targeting KRAS, highlighting the potential of miR-134 as a candidate therapeutic target in glioma patients.
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